Insulet Corp.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ashley McEvoy
- Full Time Employees
- 5,400
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 100 Nagog Park Acton MA United States of America 01720
- IPO Date
- May 15, 2007
- CIK
- 0001145197
- Website
- insulet.com
- Similar Companies
- Business
- Insulet Corporation (NASDAQ: PODD) is a medical device company that designs, develops, manufactures and commercializes innovative tubeless insulin delivery systems and related products primarily for people with diabetes; its flagship Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors for automated insulin dosing via a smartphone app or dedicated controller, the Omnipod DASH Insulin Management System featuring Bluetooth-enabled touchscreen control and waterproof tubeless Pods delivering continuous insulin for up to 72 hours without needles, the Omnipod GO pre-filled disposable Pod system for type 2 diabetes patients requiring basal insulin, and the core Omnipod Insulin Management System offering wearable needle-free delivery; the company also pursues applications of its Pod technology for non-insulin subcutaneous drug delivery in other therapeutic areas through its Drug Delivery segment. Headquartered in Acton, Massachusetts, and founded in 2000, Insulet operates highly automated manufacturing facilities with key geographic presence in the US, Europe, Asia Pacific, the Middle East, Australia and select emerging markets including China and Malaysia, serving approximately 500,000 global customers across 25 countries. In recent developments, the company completed acquisitions of automated insulin delivery assets from Bigfoot Biomedical and Automated Glucose Control LLC for $25 million each to bolster its Omnipod 5 technology, announced a proposed $450 million senior unsecured notes offering due 2033 and amendments to its credit agreement extending revolving credit facility maturity to 2030 with commitments increased to $500 million to redeem its 0.375% Convertible Senior Notes due 2026 including the remaining $380 million principal, integrated Omnipod 5 with Dexcom G7 in multiple European markets alongside new CGM reimbursements in Norway, extended its supply agreement with NXP USA effective 2025 for critical manufacturing components, redeemed outstanding convertible notes, and raised its fiscal 2025 revenue growth guidance to 28-29% at constant currency while outlining a long-term strategy targeting 20% revenue CAGR through 2028 driven by global expansion, operational efficiencies and innovation.
Company News
Insulet Announces Omnipod Discover Now Available in U.S.
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
California State Teachers Retirement System Has $2.22 Billion Stock Position in Insulet Corporation $PODD
Insulet Corporation $PODD Stock Position Raised by Amundi
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Here's Why Insulet (PODD) is a Strong Growth Stock
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
Insulet (PODD) is a Top-Ranked Value Stock: Should You Buy?
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?
Baron SMID Cap ETF Q2 2026 Portfolio Activity
PODD DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026
PODD DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026
PODD DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important August 31 Deadline in Securities Class Action - PODD
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm
Levi & Korsinsky Reminds Insulet Corporation Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 31, 2026 - PODD